Consolidated Financial Results for the Six Months Ended September 30, 2025
[Under Japanese GAAP]

November 7, 2025
Tokyo Stock Exchange

Company name: KYORIN Pharmaceutical Co., Ltd.
Code number: 4569
Web site: https://www.kyorin-pharm.co.jp/
Representative : Yutaka Ogihara, Representative Director, President and Chief Executive Officer
Contact: Sakurou Banba, Director, Finance & Accounting
TEL (03) 6374-9704

Scheduled date to commence dividend payments: December 2, 2025
Preparation of supplementary material on financial results: Yes
Holding of financial results briefing: Yes

(Amounts rounded down to the nearest million yen)

1. Consolidated results for the six months ended September 30, 2025 (from April 1, 2025 to September 30, 2025)

(1) Consolidated operating results

(Percentage changes relative to previous corresponding period)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Six months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
September 30, 2025	58,731	6.5	1,363	−12.0	1,582	−22.8	1,494	19.0
September 30, 2024	55,139	0.4	1,549	16.0	2,050	29.9	1,255	−33.6

(Note) Comprehensive income: For the six months ended September 30, 2025: 2,308 million yen (100.3%),
For the six months ended September 30, 2024: 1,152 million yen (−52.8%)

	Earnings per share (Basic)	Earnings per share (Diluted)
Six months ended	Yen	Yen
September 30, 2025	26.01	—
September 30, 2024	21.86	—

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio
As of	Million yen	Million yen	%
September 30, 2025	186,013	136,448	73.4
March 31, 2025	193,618	136,285	70.4

(Note) Equity: For the six months ended September 30, 2025: 136,448 million yen,
For the fiscal year ended March 31, 2025: 136,285 million yen

2. Dividends

	Annual dividends per share				
(Record date)	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2025	—	20.00	—	37.00	57.00
Fiscal year ending March 31, 2026	—	20.00			
Fiscal year ending March 31, 2026 (Forecast)			—	37.00	57.00

(Note) 1. Revisions to the dividend forecast in the current quarter: None
2. Breakdown of year-end dividend for the fiscal 2024: Ordinary dividend 32.00 yen, Special dividend; 5.00 yen

3. Forecast of consolidated for the year ending March 31, 2026 (from April 1, 2025 to March 31, 2026)

(Percentage changes relative to previous corresponding period)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	127,000	−2.4	6,100	−51.5	6,300	−52.3	4,800	−47.2	83.55

(Note) Revisions to the dividend forecast in the current quarter: None

4. Other

(1) Changes in significant subsidiaries during the period (Change in specified subsidiaries resulting in the scope of consolidation): None

Newly included: None, Excluded: None

(2) Adoption of accounting treatment specific to the preparation of quarterly financial statements : Yes

(3) Changes in accounting policies, changes in accounting estimates and restatements

(i) Changes in accounting policies due to revisions to accounting standards and other regulations	:None
(ii) Changes in accounting policies due to other than (i)	:None
(iii) Changes in accounting estimates	:None
(iv) Restatements	:None

(4) Number of shares issued (common stock)

(i) Number of issued shares at the end of the period (including treasury shares)
As of September 30, 2025: 59,945,641 shares,
Fiscal year ended March 31, 2025: 64,607,936 shares

(ii) Number of treasury shares at the end of the period
As of September 30, 2025: 2,493,974 shares,
Fiscal year ended March 31, 2025: 7,159,087 shares

(iii) Averaged number of shares of during the period
As of September 30, 2025: 57,449,310 shares,
As of September 30, 2024: 57,448,812 shares

* This quarterly financial report is not subject to audit procedures by Certified Public Accountants or audit firm.

* Explanations about the appropriate use of the business forecasts and other noteworthy points.

These forecast performance figures are based on information currently available to the Company and may include uncertain factors or risk that affect our future performance. Accordingly, actual business results may materially differ from the forecasted figures due to various factors in the future.

(Methods for obtaining supplementary materials and content of financial results disclosure)

The Company plans to hold the financial results briefing for investment analysts and institutional investors on Monday, November 10, 2025. Supplementary materials will be made available on the Company’s website in conjunction with the Summary of Consolidated Financial Results.